Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Published in: Cardiovascular Drugs and Therapy 1/2019

01-02-2019 | Erectile Dysfunction | REVIEW ARTICLE

Two Birds with One Stone: Regular Use of PDE5 Inhibitors for Treating Male Patients with Erectile Dysfunction and Cardiovascular Diseases

Authors: Zhonglin Cai, Jianzhong Zhang, Hongjun Li

Published in: Cardiovascular Drugs and Therapy | Issue 1/2019

Login to get access

Abstract

Patients with cardiovascular disease (CVD) frequently have erectile dysfunction (ED) because the two conditions have similar risk factors and potential mechanisms. The therapeutic effect of CVD is strongly dependent upon long-term management of the condition. Patients with CVD tend to have poor medication compliance, and the coexistence of ED often discourages patients with CVD from continuing their long-term CVD management, thus worsening CVD treatment compliance. The two major reasons for poor compliance are that (i) the adverse effects of cardiovascular medications on erectile function drive people to reduce the prescribed dosage or even stop taking the medications to obtain satisfactory sexual arousal and (ii) a worsening mental state due to ED reduces medication compliance. The regular administration of phosphodiesterase-5 inhibitors (PDE5is) guarantees that the prescribed medication dosages are easy to comply with and that they improve the mental status of patients by enhancing their erectile function, resulting in improved long-term management of CVD through medication compliance. PDE5is themselves also play a role in reducing cardiovascular events and improving the prognosis. We recommend prescribing PDE5is for ED and suggest that PDE5i administration is a promising strategy to improve the long-term management of patients with both ED and CVD.
Literature
1.
2.
Rew KT, Heidelbaugh JJ. Erectile dysfunction. Am Fam Physician. 2016;94(10):820–7.PubMed
3.
Imprialos KP, Stavropoulos K, Doumas M, et al. Sexual dysfunction, cardiovascular risk and effects of pharmacotherapy. Curr Vasc Pharmacol. 2018;16(2):130–42.CrossRefPubMed
4.
Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, et al. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes. 2013;6(1):99–109.CrossRefPubMed
5.
Uddin SMI, Mirbolouk M, Dardari Z, et al. Erectile dysfunction as an independent predictor of future cardiovascular events: the multi-ethnic study of atherosclerosis. Circulation. 2018, pii: CIRCULATIONAHA.118.033990.
6.
Ho CH, Wu CC, Chen KC, et al. Erectile dysfunction, loss of libido and low sexual frequency increase the risk of cardiovascular disease in men with low testosterone. Aging Male. 2016;19(2):96–101.CrossRefPubMed
7.
Turek SJ, Hastings SM, Sun JK, et al. Sexual dysfunction as a marker of cardiovascular disease in males with 50 or more years of type 1 diabetes. Diabetes Care. 2013;36(10):3222–6.CrossRefPubMedPubMedCentral
8.
Hwang IC, Kim YJ, Park JB, et al. Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials. BMC Cardiovasc Disord. 2017;17(1):150.CrossRefPubMedPubMedCentral
9.
Mátyás C, Németh BT, Oláh A, et al. Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes. Eur J Heart Fail. 2017;19(3):326–36.CrossRefPubMed
10.
Imai Y, Kariya T, Iwakiri M, et al. Sildenafil ameliorates right ventricular early molecular derangement during left ventricular pressure overload. PLoS One. 2018;13(4):e0195528.CrossRefPubMedPubMedCentral
11.
Lee KH, Kwon SJ, Woo JS, et al. Effects of sildenafil on nanostructural and nanomechanical changes in mitochondria in an ischaemia-reperfusion rat model. Clin Exp Pharmacol Physiol. 2014;41(10):763–8.CrossRefPubMed
12.
Frankenreiter S, Bednarczyk P, Kniess A, et al. cGMP-elevating compounds and ischemic conditioning provide cardioprotection against ischemia and reperfusion injury via cardiomyocyte-specific BK channels. Circulation. 2017;136(24):2337–55.CrossRefPubMed
13.
Banks E, Joshy G, Abhayaratna WP, et al. Erectile dysfunction severity as a risk marker for cardiovascular disease hospitalisation and all-cause mortality: a prospective cohort study. PLoS Med. 2013;10(1):e1001372.CrossRefPubMedPubMedCentral
14.
Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099.CrossRefPubMedPubMedCentral
15.
Miner M, Nehra A, Jackson G, et al. All men with vasculogenic erectile dysfunction require a cardiovascular workup. Am J Med. 2014;127(3):174–82.CrossRefPubMed
16.
Schouten BW, Bohnen AM, Bosch JL, et al. Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study. Int J Impot Res. 2008;20(1):92–9.CrossRefPubMed
17.
Compostella L, Compostella C, Truong LV, et al. History of erectile dysfunction as a predictor of poor physical performance after an acute myocardial infarction. Eur J Prev Cardiol. 2017;24(5):460–7.CrossRefPubMed
18.
19.
Andersson DP, Trolle Lagerros Y, Grotta A, et al. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart. 2017;103(16):1264–70.CrossRefPubMed
20.
Tobler D, Bouchardy J, Reto E, et al. Effect of phosphodiesterase-5 inhibition with tadalafil on systemic right ventricular size and function—a multi-center, double-blind, randomized, placebo-controlled clinical trial—serve trial—rational and design. Int J Cardiol. 2017;243:354–9.CrossRefPubMed
21.
Westermann D, Becher PM, Lindner D, et al. Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. Basic Res Cardiol. 2012;107(6):308.CrossRefPubMed
22.
23.
Lee TM, Chen CC, Chung TH, et al. Effect of sildenafil on ventricular arrhythmias in post-infarcted rat hearts. Eur J Pharmacol. 2012;690(1–3):124–32.CrossRefPubMed
24.
Mennander AA, Vuohelainen V, Aanismaa RS, et al. Sildenafil after cardiac arrest and infarction; an experimental rat model. Scand Cardiovasc J Suppl. 2013;47(1):58–64.CrossRefPubMed
25.
Anderson SG, Hutchings DC, Woodward M, et al. Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. Heart. 2016;102(21):1750–6.CrossRefPubMed
26.
Hackett G, Jones PW, Strange RC, et al. Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes. World J Diabetes. 2017;8(3):104–11.CrossRefPubMedPubMedCentral
27.
Hackett G, Heald AH, Sinclair A, et al. Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins. Int J Clin Prxzact. 2016;70(3):244–53.CrossRef
28.
Wallis RM, Corbin JD, Francis SH, et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 1999;83(5A):3C–12C.CrossRefPubMed
29.
Chau VQ, Salloum FN, Hoke NN, et al. Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. Am J Physiol Heart Circ Physiol. 2011;300(6):H2272–9.CrossRefPubMedPubMedCentral
30.
De Bon E, Bonanni G, Saggiorato G, et al. Effects of tadalafil on platelets and endothelium in patients with erectile dysfunction and cardiovascular risk factors: a pilot study. Angiology. 2010;61(6):602–6.CrossRefPubMed
31.
Halcox JP, Nour KR, Zalos G, et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol. 2002;40(7):1232–40.CrossRefPubMed
32.
Hutchings DC, Anderson SG, Caldwell JL, et al. Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? Heart. 2018. pii: heartjnl-2017-312865.
33.
Wilson LS, Elbatarny HS, Crawley SW, et al. Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-mediated regulation of platelet functions. Proc Natl Acad Sci U S A. 2008;105(36):13650–5.CrossRefPubMedPubMedCentral
34.
Makhoul S, Walter E, Pagel O, et al. Effects of the NO/soluble guanylate cyclase/cGMP system on the functions of human platelets. Nitric Oxide. 2018;76:71–80.CrossRefPubMed
35.
Bodie SL, Ford I, Greaves M, et al. Thrombin-induced activation of RhoA in platelet shape change. Biochem Biophys Res Commun. 2001;287(1):71–6.CrossRefPubMed
36.
Libersan D, Rousseau G, Merhi Y. Differential regulation of P-selectin expression by protein kinase A and protein kinase G in thrombin-stimulated human platelets. Thromb Haemost. 2003;89(2):310–7.CrossRefPubMed
37.
Jensen BO, Selheim F, Døskeland SO, et al. Protein kinase A mediates inhibition of the thrombin-induced platelet shape change by nitric oxide. Blood. 2004;104(9):2775–82.CrossRefPubMed
38.
Tham YK, Bernardo BC, Ooi JY, et al. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol. 2015;89(9):1401–38.CrossRefPubMed
39.
Koitabashi N, Aiba T, Hesketh GG, et al. Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition. J Mol Cell Cardiol. 2010;48(4):713–24.CrossRefPubMed
40.
Takimoto E, Koitabashi N, Hsu S, et al. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest. 2009;119(2):408–20.PubMedPubMedCentral
41.
Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol. 2005;25(9):1767–75.CrossRefPubMed
42.
Salloum FN, Chau VQ, Hoke NN, et al. Tadalafil prevents acute heart failure with reduced ejection fraction in mice. Cardiovasc Drugs Ther. 2014;28(6):493–500.CrossRefPubMedPubMedCentral
43.
Li N, Yuan Y, Li S, et al. PDE5 inhibitors protect against post-infarction heart failure. Front Biosci (Landmark Ed). 2016;21:1194–210.CrossRef
44.
Gong W, Duan Q, Cai Z, et al. Chronic inhibition of cGMP-specific phosphodiesterase 5 suppresses endoplasmic reticulum stress in heart failure. Br J Pharmacol. 2013;170(7):1396–409.CrossRefPubMedPubMedCentral
45.
Corinaldesi C, Di Luigi L, Lenzi A, et al. Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications. J Endocrinol Investig. 2016;39(2):143–51.CrossRef
46.
Gong W, Yan M, Chen J, et al. Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis through inhibition of transforming growth factor β-induced Smad signaling. Front Med. 2014;8(4):445–55.CrossRefPubMed
47.
Kukreja RC, Salloum FN, Das A. Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. J Am Coll Cardiol. 2012;59(22):1921–7.CrossRefPubMedPubMedCentral
48.
Frankenreiter S, Groneberg D, Kuret A, et al. Cardioprotection by ischemic postconditioning and cyclic guanosine monophosphate-elevating agents involves cardiomyocyte nitric oxide-sensitive guanylyl cyclase. Cardiovasc Res. 2018;114(6):822–9.CrossRefPubMed
49.
Behmenburg F, Dorsch M, Huhn R, et al. Impact of mitochondrial Ca2+-sensitive potassium (mBKCa) channels in sildenafil-induced cardioprotection in rats. PLoS One. 2015;10(12):e0144737.CrossRefPubMedPubMedCentral
50.
Francis SH, Busch JL. Corbin JD, et al. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev. 2010;62(3):525–63.CrossRefPubMedPubMedCentral
51.
Gao Y. Conventional and unconventional mechanisms for soluble guanylyl cyclase signaling. J Cardiovasc Pharmacol. 2016;67(5):367–72.CrossRefPubMed
52.
Thenappan T, Ormiston ML, Ryan JJ, et al. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018;j5492:360.
53.
Yamamura A, Fujitomi E, Ohara N, et al. Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro. Eur J Pharmacol. 2017;810:44–50.CrossRefPubMed
54.
Li B, Yang L, Shen J, et al. The antiproliferative effect of sildenafil on pulmonary artery smooth muscle cells is mediated via upregulation of mitogen-activated protein kinase phosphatase-1 and degradation of extracellular signal-regulated kinase 1/2 phosphorylation. Anesth Analg. 2007;105(4):1034–41 table of contents.CrossRefPubMed
55.
Wang J, Yang K, Xu L, et al. Sildenafil inhibits hypoxia-induced transient receptor potential canonical protein expression in pulmonary arterial smooth muscle via cGMP-PKG-PPARγ axis. Am J Respir Cell Mol Biol. 2013;49(2):231–40.CrossRefPubMedPubMedCentral
56.
Wang C, Wang J, Zhao L, et al. Sildenafil inhibits human pulmonary artery smooth muscle cell proliferation by decreasing capacitative Ca2+ entry. J Pharmacol Sci. 2008;108(1):71–8.CrossRefPubMed
57.
58.
Washington SL 3rd, Shindel AW. A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. Drug Des Devel Ther. 2010;4:159–71.PubMedPubMedCentral
59.
Lane-Cordova AD, Kershaw K, Liu K, et al. Association between cardiovascular health and endothelial function with future erectile dysfunction: the multi-ethnic study of atherosclerosis. Am J Hypertens. 2017;30(8):815–21.CrossRefPubMedPubMedCentral
60.
Özdabakoğlu O, Güllülü S, Sağ S, et al. Evaluation of arterial stiffness and cardiac function in patients with vascular erectile dysfunction: acute effects of phosphodiesterase-5 inhibitor tadalafil. Int J Impot Res. 2017;29(3):96–100.CrossRefPubMed
61.
Kempler P, Amarenco G, Freeman R, et al. Management strategies for gastrointestinal, erectile, bladder, and sudomotor dysfunction in patients with diabetes. Diabetes Metab Res Rev. 2011;27(7):665–77.CrossRefPubMed
62.
Qiu S, Tang Z, Deng L, et al. Comparisons of regular and on-demand regimen of PED5-Is in the treatment of ED after nerve-sparing radical prostatectomy for Prostate Cancer. Sci Rep. 2016;6:32853.CrossRefPubMedPubMedCentral
63.
Javaroni V, Queiroz Miguez M, Burla A, et al. Response to on-demand vardenafil was improved by its daily usage in hypertensive men. Urology. 2012;80(4):858–64.CrossRefPubMed
64.
Kim E, Seftel A, Goldfischer E, et al. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil. Curr Med Res Opin. 2015;31(2):379–89.CrossRefPubMed
65.
Hackett G, Krychman M, Baldwin D, et al. Coronary heart disease, diabetes, and sexuality in men. J Sex Med. 2016;13(6):887–904.CrossRefPubMed
66.
Kratz MT, Schirmer SH, Baumhäkel M, et al. Improvement of endothelial function in a murine model of mild cholesterol-induced atherosclerosis by mineralocorticoid antagonism. Atherosclerosis. 2016;251:291–8.CrossRefPubMed
67.
Pernow J, Jung C. The emerging role of arginase in endothelial dysfunction in diabetes. Curr Vasc Pharmacol. 2016;14(2):155–62.CrossRefPubMed
68.
Jamshidian H, Borhan A, Kooraki S, et al. Evaluation of the efficacy of once-daily use of tadalafil vs. on-demand use. Is there a cumulative effect? J Pak Med Assoc. 2012;62(11):1195–8.PubMed
69.
Ilic D, Hindson B, Duchesne G, et al. A randomised, double-blind, placebo-controlled trial of nightly sildenafil citrate to preserve erectile function after radiation treatment for prostate cancer. J Med Imaging Radiat Oncol. 2013;57(1):81–8.CrossRefPubMed
70.
Choi H, Kim JH, Shim JS, et al. Comparison of the efficacy and safety of 5-mg once-daily versus 5-mg alternate-day tadalafil in men with erectile dysfunction and lower urinary tract symptoms. Int J Impot Res. 2015;27(1):33–7.CrossRefPubMed
71.
Caglayan E, Huntgeburth M, Karasch T, et al. Phosphodiesterasetype 5 inhibition is a novel therapeutic option in Raynaud’s disease. Arch Intern Med. 2006;166:231–3.CrossRefPubMed
72.
Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in thetreatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation. 2005;112:2980–5.CrossRefPubMed
73.
Rubin LJ, Badesch DB, Flemming TR, et al. Long-term treatmentwith sildenafil citrate in pulmonary arterial hypertension. TheSUPER-2 Study. Chest. 2011;140:1274–83.CrossRefPubMed
74.
Jing ZC, Shen JY, Wu BX, et al. Vardenafil for the treatment ofpulmonary arterial hypertension. Am J Respir Crit Care Med. 2011;183:1723–9.CrossRefPubMed
75.
Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy inpulmonary arterial hypertension 2009;119:2894–903.
76.
77.
Nera A. Erectile dysfunction and cardiovascular disease: efficacyand safety of phosphodiesterase type 5 inhibitors in men with bothcondtions. Mayo Clin Proc. 2009;84:139–48.CrossRef
78.
Oliver JJ, Dear JW, Webb DJ. Clinical potential of combinedorganic nitrate and phosphodiesterase type 5 inhibitor in treatmentresistant hypertension. Hypertension. 2010;56:62–7.CrossRefPubMed
79.
Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5inhibitors approved for the treatment of erectile dysfunction. Circulation. 2004;110:3149–55.CrossRefPubMed
80.
Kloner RA. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol. 2005;96(12B):42M–6M.CrossRefPubMed
81.
Dadkhah F, Safarinejad MR, Asgari MA, et al. Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil. Int J Impot Res. 2010;22(1):51–60.CrossRefPubMed
82.
83.
Elias-Al-Mamun M, Satoh K, Tanaka S, et al. Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension and survival in rats. Circ J. 2014;78(4):967–76.CrossRefPubMed
84.
El-Sisi AE, Sokar SS, Abu-Risha SE, et al. Combination of tadalafil and diltiazem attenuatesrenal ischemia reperfusion-induced acute renal failure in rats. Biomed Pharmacother. 2016;84:861–9.CrossRefPubMed
85.
Zullig LL, Ramos K3, Bosworth HB. Improving medication adherence in coronary heart disease. Curr Cardiol Rep. 2017;19(11):113.CrossRefPubMed
86.
Kim J, Lee HS, Nam CM, et al. Effects of statin intensity and adherence on the long-term prognosis after acute ischemic stroke. Stroke. 2017;48(10):2723–30.CrossRefPubMed
87.
Xie G, Sun Y, Myint PK, et al. Six-month adherence to statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes. Lipids Health Dis. 2017;16(1):155.CrossRefPubMedPubMedCentral
88.
Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005 Jun;43(6):521–30.CrossRefPubMed
89.
Rosen RC. Sexual dysfunction as an obstacle to compliance with antihypertensive therapy. Blood Press Suppl. 1997;1:47–51.PubMed
90.
Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61.CrossRefPubMed
91.
Fogari R, Zoppi A, Poletti L, et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens. 2001;14:27–31.CrossRefPubMed
92.
Voils CI, Sandelowski M, Dahm P, et al. Selective adherence to antihypertensive medications as a patient-driven means to preserving sexual potency. Patient Prefer Adherence. 2008;2:201–6.CrossRefPubMedPubMedCentral
93.
Kimura M, Shimura S, Tai T, et al. A web-based survey of erection hardness score and its relationship to aging, sexual behavior, confidence, and risk factors in Japan. Sex Med. 2013;1(2):76–86.CrossRefPubMedPubMedCentral
94.
Intili H, Nier D. Self-esteem and depression in men who present with erectile dysfunction. Urol Nurs. 1998;18:185–7.PubMed
95.
Martin-Morales A, Meijide Rico F, Garcia Gonzalez JI, et al. Psychological impact of erectile dysfunction on self-esteem and self-confidence. Actas Urol Esp. 2005;29:493–8.CrossRefPubMed
96.
Shabsigh R, Klein LT, Seidman S, et al. Increased incidence of depressive symptoms in men with erectile dysfunction. Urology. 1998;52:848–52.CrossRefPubMed
97.
Hare DL, Toukhsati SR, Johansson P, et al. Depression and cardiovascular disease: a clinical review. Eur Heart J. 2014;35(21):1365–72.CrossRefPubMed
98.
Ju A, Hanson CS, Banks E, et al. Patient beliefs and attitudes to taking statins: systematic review of qualitative studies. Br J Gen Pract. 2018;68(671):e408–19.CrossRefPubMedPubMedCentral
99.
Janssen-Niemeijer AJ, Visse M, Van Leeuwen R, et al. The role of spirituality in lifestyle changing among patients with chronic cardiovascular diseases: a literature review of qualitative studies. J Relig Health. 2017;56(4):1460–77.CrossRefPubMed
100.
Mazzola CR, Deveci S, Teloken P, et al. Exploring the association between erectile rigidity and treatment adherence with sildenafil. J Sex Med. 2013;10(7):1861–6.CrossRefPubMed
101.
Smith WB 2nd, McCaslin IR, Gokce A, et al. PDE5 inhibitors: considerations for preference and long-term adherence. Int J Clin Pract. 2013;67(8):768–80.CrossRefPubMed
102.
Peng Z, Yang L, Dong Q, et al. Efficacy and safety of tadalafil once-a-day versus tadalafil on-demand in patients with erectile dysfunction: a systematic review and meta-analyses. Urol Int. 2017;99(3):343–52.CrossRefPubMed
103.
Bansal UK, Jones C, Fuller TW, et al. The efficacy of tadalafil daily vs on demand in the treatment of erectile dysfunction: a systematic review and meta-analysis. Urology. 2018;112:6–11.CrossRefPubMed
104.
Bosworth HB, Blalock DV, Hoyle RH, et al. The role of psychological science in efforts to improve cardiovascular medication adherence. Am Psychol. 2018;73(8):968–80.CrossRefPubMedPubMedCentral
105.
Costa P, Grandmottet G, Mai HD, et al. Impact of a first treatment with phosphodiesterase inhibitors on men and partners’ quality of sexual life: results of a prospective study in primary care. J Sex Med. 2013;10(7):1850–60.CrossRefPubMed
106.
Gong B, Ma M, Xie W, et al. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int Urol Nephrol. 2017;49(10):1731–40.CrossRefPubMedPubMedCentral
107.
Tinel H, Stelte-Ludwig B, Hütter J, et al. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int. 2006;98(6):1259–63.CrossRefPubMed
108.
Brousil P, Shabbir M, Zacharakis E, et al. PDE-5 inhibitors for BPH-associated LUTS. Curr Drug Targets. 2015;16(11):1180–6.CrossRefPubMed
109.
Cellek S, Cameron NE, Cotter MA, et al. Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS. Nat Rev Urol. 2014;11(4):231–41.CrossRefPubMed
110.
Seftel AD, de la Rosette J, Birt J, et al. Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. Int J Clin Pract. 2013;67(1):32–45.CrossRefPubMed
111.
Korneyev IA, Alexeeva TA, Al-Shukri SH, et al. Prevalence and risk factors for erectile dysfunction and lower urinary tract symptoms in Russian Federation men: analysis from a national population-based multicenter study. Int J Impot Res. 2016;28(2):74–9.CrossRefPubMed
112.
Song J, Shao Q, Tian Y, et al. Lower urinary tract symptoms, erectile dysfunction, and their correlation in men aged 50 years and above: a cross-sectional survey in Beijing, China. Med Sci Monit. 2014;20:2806–10.CrossRefPubMedPubMedCentral
113.
Gacci M, Carini M, Salvi M, et al. Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors. Drugs Aging. 2014;31(6):425–39.CrossRefPubMed
114.
Mónica FZ, Antunes E. Stimulators and activators of soluble guanylate cyclase for urogenital disorders. Nat Rev Urol. 2018;15(1):42–54.CrossRefPubMed
Metadata
Title
Two Birds with One Stone: Regular Use of PDE5 Inhibitors for Treating Male Patients with Erectile Dysfunction and Cardiovascular Diseases
Authors
Zhonglin Cai
Jianzhong Zhang
Hongjun Li
Publication date
01-02-2019
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 1/2019
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-019-06851-7

Other articles of this Issue 1/2019

Cardiovascular Drugs and Therapy 1/2019 Go to the issue

ORIGINAL ARTICLE

Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the “Cardiac Benefits” of Empagliflozin Independent of its Hypoglycemic Activity?

ORIGINAL ARTICLE

Inhibition of Phosphoglycerate Mutase 5 Reduces Necroptosis in Rat Hearts Following Ischemia/Reperfusion Through Suppression of Dynamin-Related Protein 1

SHORT COMMUNICATION

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia

REVIEW ARTICLE

Risk Assessment of Stroke in Patients with Atrial Fibrillation: Current Shortcomings and Future Directions

ORIGINAL ARTICLE

Revisiting the Cardiotoxic Effect of Chloroquine

ORIGINAL ARTICLE

Rationale, Design, and Baseline Characteristics of the Prospective Japan Acute Myocardial Infarction Registry (JAMIR)

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits